Fibromyalgia
Conditions
Brief summary
While walking exercises performed outdoors are important within the scope of aerobic exercise, the continuity of outdoor walking exercises can be negatively affected by different weather conditions. Walking exercises performed indoors on a treadmill are a good option for patients in terms of increasing exercise continuity and patient compliance. Walking outdoors supported by a treadmill and mobile application may increase aerobic capacity and quality of life in patients with fibromyalgia syndrome, as well as reduce kinesiophobia.
Interventions
OTHERWalking exercises with treadmill
Patients will be enrolled in a treadmill exercise program in the cardiopulmonary exercise unit for 45 minutes, 3 days a week for 4 weeks.
OTHERWalking exercises at open air place
Patients will walk briskly outdoors for 45 minutes, 3 days a week for 4 weeks. Patients will receive notifications via a mobile app reminding them of their daily walk, and they will be asked to log their walks in the mobile app.
Sponsors
Ankara Etlik City Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
25 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
1. Be between the ages of 25 and 55 2. Be female 3. Have not engaged in regular physical activity for the past 3 months 4. Have been using the same medical treatment for at least 1 month prior to the study (amitriptyline, duloxetine/milnacipran, pregabalin, cyclobenzaprine) 5. Volunteering to participate in the study 6. The patient's cognitive status being suitable for using a mobile application 7. The patient agreeing to the 'Personal Data Protection Law Information Text' in order to use the mobile application
Exclusion criteria
1. History of cardiac or pulmonary disease 2. Changes in medical treatment during the study period 3. Use of different injection methods (ozone therapy, neural therapy, acupuncture, etc.) at least 3 months prior to the study or during the study period 4. History of rheumatological disease 5. Pregnancy or breastfeeding 6. History of malignancy 7. Presence of psychiatric or neurological disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 6-minute walk test | First day of treatment, at the end of 4 week |
Secondary
| Measure | Time frame |
|---|---|
| Fibromyalgia Impact Questionnaire (FIQ) | First day of treatment, at the end of 4 week |
| Measurement of maximum inspiratory and expiratory pressure (MIP) and (MEP) | First day of treatment, at the end of 4 week |
| Beck Depression Scale | First day of treatment, at the end of 4 week |
| Fatigue Impact Scale | First day of treatment, at the end of 4 week |
| Short Form-36 (SF-36) | First day of treatment, at the end of 4 week |
Countries
Turkey (Türkiye)
Contacts
CONTACTAyşe Naz Kalem Özgen, Specialist
Outcome results
None listed